The papain-like protease of avian infectious bronchitis virus has deubiquitinating activity

Liping Yu¹ • Xiaorong Zhang¹ • Tianqi Wu¹ • Yuyang Wang¹ • Jie Meng¹ • Qian Liu¹ • Xiaosai Niu¹ • Yantao Wu¹

Received: 21 November 2016 / Accepted: 13 February 2017 / Published online: 18 March 2017
© Springer-Verlag Wien 2017

Abstract Coronavirus papain-like proteases (PLPs) can act as proteases that process virus-encoded large replicase polyproteins and also as deubiquitinating (DUB) enzymes. Like the PLPs of other coronaviruses (CoVs), the avian infectious bronchitis virus (IBV) PLP catalyzes proteolysis of Gly-Gly dipeptide bonds to release mature cleavage products. However, the other functions of the IBV PLP are not well understood. In this study, we found that IBV exhibits strong global DUB activity with significant reductions of the levels of ubiquitin (Ub)-, K48-, and K63-conjugated proteins. The DUB activity exhibited a clear time dependence, with stronger DUB activity in the early stage of viral infection. Furthermore, the IBV replicase-encoded PLP, including the downstream transmembrane (TM) domain, is a DUB enzyme and dramatically reduced the level of Ub-conjugated proteins, while processing both K48- and K63-linked polyubiquitin chains. By contrast, PLP did not cause any reduction of haemagglutinin (HA)-Ub-conjugated proteins. In addition, mutations of the catalytic residues of PLP-TM, Cys1274Ser and His1437Lys, reduced DUB activity against Ub-, K48- and K63-conjugated proteins, indicating that the DUB activity of the PLP-TM wild-type protein is not completely dependent on its catalytic activity. Overall, these results demonstrate that the IBV-encoded PLP-TM functions as a DUB enzyme and suggest that IBV may interfere with the activation of host antiviral signaling pathway by degrading polyubiquitin-associated proteins.

Introduction

Avian infectious bronchitis virus (IBV) is the prototype of gamma coronaviruses (CoV), a family of enveloped viruses that possess a large continuous positive-stranded RNA genome [4]. The genomic RNA is 27.6 kb in length, and approximately two thirds of the nucleotide sequence encodes ORF 1, which includes ORF 1a and ORF 1b [11, 22–25]. A papain-like protease (PLP) is encoded by the region from nucleotides 4243 to 5553 of ORF 1a [21], comprising the catalytic domain of nonstructural protein 3 (nsp3). Proteolysis at the Gly673-Gly674 and Gly2265–Gly2266 dipeptide bonds leads to release of the 87-kDa and 195-kDa N-terminal mature proteins and the C-terminal 41-kDa cleavage product [20, 21, 23]. Site-directed mutagenesis studies have confirmed that the Cys1274 and His1437 residues of PLP are essential for proteinase activity [20].

CoVs such as the human coronavirus NL63 (HCoV-NL63) [6] and murine hepatitis virus-A59 (MHV-A59) [2] encode two functional papain-like proteases (PLP), termed PLP1 and PLP2. At least two CoVs, severe acute respiratory syndrome coronavirus (SARS-CoV) [1] and IBV [21] encode only one functional papain-like protease, termed PLP. The proteolytic processing mediated by the PLP encoded by IBV [20] is similar to that of PLP2 encoded by other CoVs [3, 6]. PLPs of CoVs also perform deubiquitinating (DUB) and interferon (IFN) antagonism activities. For instance, PLP2 of MHV-A59 [29] can bind to IRF3, cause its deubiquitination and prevent its nuclear translocation, thus inhibiting cellular IRF3-mediated type I IFN

L. Yu and X. Zhang Equal contributors.

*Yantao Wu
ywu@yzu.edu.cn

¹ Jiangsu Co-Innovation Center for Prevention of Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, Jiangsu, China
production and promoting viral infection. The SARS-CoV PLP pro-catalytic core also has DUB activity and can deubiquitinate IRF3, thereby stalling its migration to the nucleus and preventing the host antiviral response [7, 10, 26]. Similarly, purified PLP2 of HCoV–NL63 can hydrolyze K48-linked hexa-ubiquitin (K48-Ub6) to produce monoubiquitin [6, 7], and therefore negatively regulate antiviral defenses by disrupting the STING-mediated IFN induction [26].

Structural and enzymatic studies have revealed that CoVs PLPs can act as both a protease, to process virus-encoded large replicase polyproteins, and a DUB enzyme, to cleave the isopeptide bonds found in polyubiquitin chains [7, 20]. Here, we demonstrate that IBV has DUB activity, and like other CoVs, IBV can recognize and process both K48- and K63-linked polyubiquitin chains. We also demonstrate that the core domain of IBV PLP-TM is a coronavirus DUB enzyme. We also evaluated the role of PLP catalytic activity in DUB activity and found that PLP-TM does not require catalytic activity to cleave polyubiquitin-linked proteins. This study represents a first step in elucidating the role of PLP-TM in IBV pathogenesis and provides new insights on how IBV escapes host antiviral immune mechanisms.

Materials and methods

Cells and virus

Chicken embryonic kidney (CEK) cells were aseptically generated from 20-day-old specific pathogen-free (SPF) chicken embryos (Beijing Merial Vital Laboratory Animal Technology Company). The cell suspension was obtained by trypsinization of kidneys for 30 min at 37°C and subsequent filtration through a 100-μm mesh. The cells were then cultured in M199 medium (Hyclone) supplemented with 3% fetal bovine serum (FBS). The DF1 chicken fibroblast cell line was used for all transfection-based assays. The cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Hyclone) supplemented with 10% FBS.

IBV (JS/2010/12 strain, GenBank accession no. JQ900122.1) was cultured in 10-day SPF chicken embryos or CEK cells. The initial IBV stock was inoculated in chicken embryos for six passages (P6). This study was conducted based on this P6 stock of IBV. The 50% tissue culture infective dose (TCID50) of the IBV P6 stock was determined by identifying the cytopathic effect (CPE) of the virus in CEK cells.

Plasmids

The plasmid pcDNA-5’ flag was a kind gift from Dr. Meng (Dalian Medical University). pRK5-HA-Ub and the mutant derivatives pRK5-HA-Ub-K48 and pRK5–HA-Ub-K63 were obtained from Addgene (plasmids #17608, #17605 and #17606) [19]. Attachment of ubiquitin (Ub) modifiers is a reversible post-translational modification that regulates the fate and function of proteins. The ubiquitin molecule contains a total of seven lysine residues at positions 6, 11, 27, 29, 33, 48 (K48), and 63 (K63). These lysine residues potentially mediate ubiquitin chain elongation. The two most common types of polyubiquitin chains are linked through ubiquitin lysine 48 (K48) and lysine 63 (K63).

Generation of the IBV PLP and PLP-TM constructs and site-directed mutants

PLP is encoded by IBV ORF 1a at the region of nsp3 between nucleotides 4243 and 5553 [22]. Biological analysis software (TMHMM Server v. 2.0) was used to analyze the amino acid sequence of nsp3 to predict the transmembrane (TM) domain near PLP [9]. In Figure 2b, the red area indicates the transmembrane domain; the extracellular protein and short cytoplasmic domain are indicated by pink and blue, respectively (Fig. 2b).

PLP and PLP-TM constructs were generated using specific primers (Table 1) to amplify the designated

| Purpose          | Name   | Sequence (5’ → 3’) | Position |
|------------------|--------|-------------------|----------|
| Cloning of PLP   | PLP:F  | AAGATCCGGATTTGATGCGCAAAGATAT (BamH I) | 4243-4266 bp |
|                  | PLP:R  | AAATCGAGAACAATTCGAATGTAACCAACTAGTTCC (Xho I) | 5527-5553 bp |
| Cloning of PLP-TM| PLP:F  | AAGATCCGGATTTGATGCGCAAAGATAT (BamH I) | 4243-4266 bp |
|                  | PLP-TM:R | AA GCGGCCGCAATAAAAAAGCCAGAAATAAATCTT (Not I) | 6228-6252 bp |
| PLP-TM C1274S    | PLP C1274S:F | AAATGGCCGTGATGCGAAACgtGCTGGATTAGTTCAG | 4330-4363 bp |
|                  | PLP C1274S:R | GTTCTTCTACACCACATTTAAGTTAGAATAA | 4319-4347 bp |
| PLP-TM H1437K    | PLP H1437K:F | GTCCCAACACAAGTTGGAAatTGTATACACA | 4820-4851 bp |
|                  | PLP H1437K:R | GTTCCCTACTGTTGGACCAATAAAT | 4820-4851 bp |

a. The underlined nucleotides are restriction enzyme sequences and mutated sequences. Restriction enzymes are indicated in parentheses
b. All nucleotide numbers are based on the IBV JS/2010/12 strain genome sequence
regions from IBV cDNA by PCR. The amplified products of PLP (nucleotides 4243 to 5553) were cloned into pcDNA-5′ flag at the BamHI and XhoI sites as an in-frame fusion with the flag peptide. PLP, including the TM domain (nucleotides 4243 to 6252), was cloned into pcDNA-5′ flag at the BamHI and NotI sites to generate TM-containing PLP (PLP-TM) in frame with the flag peptide.

A cysteine residue (Cys 1274) and histidine residue (His 1437) of PLP are the catalytic residues of the proteinase activity [20]. Either of these two sites could play an important role in the DUB activity of PLP-TM. To explore these possibilities, substitution mutations of the Cys 1274 residue with Ser and the His 1437 residue with Lys were constructed to obtain the mutant constructs PLP-TM Cys1274Ser (PLP-TM C1274S) and PLP-TM His1437Lys (PLP-TM H1437K) [20].

To generate specific mutations of the catalytic residues, mutagenic primers (Table 1) were incorporated into newly synthesized DNA using the Fast mutagenesis system protocol (Trans, Fast Mutagenesis System, FM111) according to the manufacturer’s instructions.

**Transfection**

The transfections were performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. This method resulted in a transfection rate of at least 70%. Briefly, the plasmid (2 μg for 6-well) was diluted into opti-MEM, and Lipofectamine 2000 (5 μl for 6-well) was diluted into opti-MEM. The diluted DNA was added to diluted Lipofectamine 2000 (1:1 ratio), incubated for 5 min, and then added to the cell cultures.

**Western blot**

DF1 cells were co-transfected with pRK5-HA-Ub, pRK5-HA-Ub-K48 or pRK5-HA-Ub-K63 plasmids and the indicated amounts of IBV PLP, PLP-TM and specific catalytic mutants. The cells were then lysed in RIPA lysis buffer (Beyotime Institute of Biotechnology, China). The cell lysates were analyzed for HA-conjugated proteins using western blotting with monoclonal anti-HA antibody (1:5000, Sigma). An anti-N antibody was used to detect the viral replication level. To confirm the expression levels of PLP and the mutants, anti-flag antibody (1:5000, Sigma) was used to detect the flag-tagged proteins. Actin was detected using β-actin antibody (1:5000, Sigma) as a protein loading control.

**IBV DUB activity detection assays**

The effect of IBV on ubiquitinated proteins in cells was assessed as follows. DF1 cells were infected with IBV at a multiplicity of infection (MOI) of 10 or mock-infected. The cells were then transfected with pRK5-HA-Ub, pRK5-HA-Ub-K48 or pRK5-HA-Ub-K63 for an additional 24 h. To investigate the relationship between IBV replication and DUB activity, DF1 cells were infected with IBV at an MOI of 10 or mock-infected and then transfected with pRK5-HA-Ub at 12 h, 18 h or 24 h post-infection for an additional 24 h. Cell lysates were then prepared and the extent of protein ubiquitination was assessed by western blot as described.

**Assays for the DUB activity of PLP, PLP-TM and the catalytic mutants**

The effects of PLP, PLP-TM and the catalytic mutants on ubiquitinated proteins in cultured cells was assessed as follows. DF1 cells were co-transfected with pRK5-HA-Ub/ pRK5-HA-Ub-K48/pRK5-HA-Ub-K63 and the indicated amounts of the constructs encoding PLP-TM or the corresponding catalytic mutants. The pcDNA-5′ flag vector was used to standardize the quantity of DNA. The total cells were harvested, and ubiquitinated proteins were assessed as described previously 24 h post infection.

**Results**

**IBV has DUB activity**

To determine if IBV exhibits DUB activity against host cellular substrates after infection, DF1 cells were transfected with pRK5-HA-Ub, pRK5-HA-Ub-K48 or pRK5-HA-Ub-K63 after infection with IBV or mock infection. The levels of Ub- (Fig. 1a, lane 3), K48- (Fig. 1a, lane 5) and K63- (Fig. 1a, lane 7) conjugated proteins were reduced dramatically in DF1 cells after infection with IBV. This suggests that IBV exhibits strong DUB activity that recognizes and processes both K48- and K63-linked polyubiquitin chains. To investigate the relationship between IBV replication and DUB activity, DF1 cells were transfected with pRK5-HA-Ub at different times post-infection. Western blot analysis revealed that IBV decreased the levels of Ub-conjugated proteins at different times, and the levels of Ub-conjugated proteins were lower at 12 h than at 18 h and 24 h. Thus, IBV exhibited stronger DUB activity in the early stage of infection (Fig. 1b, lanes 3, 4 and 5; Fig. 1c). Overall, IBV has global DUB activity against ubiquitinated proteins, and the DUB activity exhibits a clear time dependence in cultured cells.

**PLP-TM, but not PLP, has DUB activity**

PLP is the catalytic domain of IBV, encoded by the genomic region from nucleotides 4243 to 5553, and the TM
The DUB activity of PLP-TM does not completely depend on its catalytic activity

PLP contained within the nsp3 has been shown to be responsible for the cleavage of ORF 1a at the two Gly-Gly dipeptide bonds to release mature protein, and the catalytic dyad for this activity was Cys1274 and His1437 [20]. Either of the two catalytic residue sites may play an important role in the DUB activity of PLP-TM. To explore these possibilities, DF1 cells were transfected with PLP-TM, PLP-TM C1274S or PLP-TM H1437K, together with pRK5-HA-Ub or pRK5-HA-Ub-K48 or pRK5-HA-Ub-K63, along with the indicated amounts of PLP-TM. Cell lysates were prepared at 24 h post-transfection and analyzed for HA–Ub–conjugated proteins by western blot with an anti-HA antibody (top panel). Anti-flag was used to confirm the expression of PLP and PLP-TM (second panel), and β-actin was detected as a loading control (bottom panel) (color figure online)

Discussion

In this study, we characterized the DUB activity of IBV PLP in DF1 cells and the core domain of the DUB activity. We found that IBV exhibits strong global DUB activity during infection of DF1 cells, indicating that IBV infection disrupts polyubiquitin modification in host cells or encodes...
a protein with DUB activity [14]. Further experiments indicated that the proteinase PLP-TM plays an important role in IBV DUB activity and can process both K48- and K63-linked polyubiquitin chains. Moreover, the DUB activity of PLP-TM was not completely dependent on its catalytic activity.
Similar to the CoV porcine epidemic diarrhea virus (PEDV) [28], the DUB activity of IBV also dramatically reduced Ub-conjugated protein levels in virus-infected cells, and the IBV PLP plays an important role in this DUB activity. PLP2 of PEDV has potent DUB activity that is dependent on its catalytic activity. In notable contrast to PEDV PLP2, the DUB activity of IBV PLP is not dependent on its protease activity. Another group reported that IBV PLP can degrade K48- and K63-linked polyubiquitin chains to monoubiquitin but cannot degrade linear polyubiquitin [18]. HCoV-NL63 PLP2 has a DUB activity that is dependent on its protease activity [7]. By contrast, both the PLP2-TM and catalytic mutants of PLP2-TM [26] had DUB activity, although the DUB activity of the PLP2-TM catalytic mutants was lower than that of PLP2-TM, suggesting that the TM domain plays a role in PLP2 DUB activity. Similarly, our study confirmed that the TM domain downstream of IBV PLP is essential for PLP DUB activity. The PLP2 of NL63 has DUB activity and antagonizes the induction of type I IFN, whereas PLP-mediated IFN antagonism is independent of DUB activity [6]. These data show that CoVs PLPs target the activity of type I IFN through DUB activity and inhibit the activation of the innate immune system.

This study raises important questions concerning the role of viral DUB activity in CoV replication and pathogenesis. Coronaviral DUB activity may target the Ub-proteasome pathway to facilitate virus replication and damage host defense mechanisms, including innate immunity [5, 8]. Some CoVs may utilize DUB activity to escape the host innate antiviral response [13, 27]. For example, PLP2 of MHV-A59 can bind to IRF3, cause its deubiquitination and prevent its nuclear translocation. Co-expression of PLP2 inhibits CARDIF-, TBK1- and IRF3-mediated IFN-β reporter activities [29]. MHV-A59 may use DUB activity to reduce IFN induction, to promote viral growth and to escape from host innate antiviral responses [29]. PEDV infection suppresses the production of IFN-β and PLP2 acts as a viral DUB to interfere with RIG-I- and STING-mediated signaling pathways [28]. However, some CoVs PLP-mediated interferon antagonism is independent on protease and DUB activity. The PLP2 of NL63 has DUB activity and antagonizes the induction of type I IFN, whereas PLP-mediated IFN antagonism is independent of DUB activity [6]. These data show that CoVs PLPs target the activity of type I IFN through DUB activity and inhibit the activation of the innate immune system.

Overall, the results of our study show that IBV has DUB activity and confirm that PLP-TM is not only a classic papain-like protease encoded by IBV but is also a multi-functional protein that plays important roles in the regulation of interactions between IBV and host innate immune system and IBV infection.
the host must be clarified to provide further insight into viral replication and pathogenesis.

Compliance with ethical standards

Funding This work was supported by the earmarked fund for Modern Agro-industry Technology Research System (Grant No. CARS-41-K08), a project supported by the National Natural Science Foundation of China (Grant No. 31101815), and a project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Conflict of interest We have no conflict of interest.

Ethical approval The Jiangsu Administrative Committee for Laboratory Animals approved all animal studies (Permit Number: SYXKSU-2007-0005) according to the guidelines of Jiangsu Laboratory Animal Welfare and Ethical of Jiangsu Administrative Committee of Laboratory Animals.

References

1. Barreto N, Jukneliene D, Ratia K, Chen Z, Mesecar AD, Baker SC (2005) The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 79:15189–15198
2. Bonilla PJ, Hughes SA, Pinon JD, Weiss SR (1995) Characterization of the leader papain-like protease of MHV-A59: identification of a new in vitro cleavage site. Virology 209:489–497
3. Bonilla PJ, Hughes SA, Weiss SR (1997) Characterization of a second cleavage site and demonstration of activity in trans by the papain-like protease of the murine coronavirus mouse hepatitis virus strain A59. J Virol 71:900–909
4. Cavanagh D (1997) Nidovirales: a new order comprising Coronavirusidae and Arteriviridae. Arch Virol 142:629–633
5. Chen M, Gerlier D (2006) Viral hijacking of cellular ubiquitination pathways as an anti-innate immunity strategy. Viral Immunol 19:349–362
6. Chen Z, Wang Y, Ratia K, Mesecar AD, Wilkinson KD, Baker SC (2007) Proteolytic processing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J Virol 81:6007–6018
7. Clementz MA, Chen Z, Banach BS, Wang Y, Sun L, Ratia K, Baez-Santos YM, Wang J, Takayama J, Ghosh AK, Li K, Mesecar AD, Baker SC (2010) Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J Virol 84:4619–4629
8. Edelmann MJ, Kessler BM (2008) Ubiquitin and ubiquitin-like specific proteases targeted by infectious pathogens: Emerging patterns and molecular principles. Biochimica et biophysica acta 1782:809–816
9. Fang S, Shen H, Wang J, Tay FP, Liu DX (2010) Functional and genetic studies of the substrate specificity of coronavirus infectious bronchitis virus 3C-like protease. J Virol 84:7325–7336
10. Frieman M, Ratia LO, Lerman A (2007) Proteolytic processing and deubiquitinating activity of coronavirus papain-like proteases. J Virol 81:6007–6018
11. Gorbatenya AE, Koonin EV, Donchenko AP, Blinov VM (1989) Coronavirus genome: prediction of putative functional domains in the non-structural polypeptide by comparative amino acid sequence analysis. Nucleic Acids Res 17:4847–4861
12. Gosert R, Kanjanahaluethai A, Egger D, Bienz K, Baker SC (2002) RNA replication of mouse hepatitis virus takes place at double-membrane vesicles. J Virol 76:3697–3708
13. Herrmann J, Lerman LO, Lerman A (2007) Ubiquitin and ubiquitin-like proteins in protein regulation. Circ Res 100:1276–1291
14. Kerscher O, Felberbaum R, Hochstrasser M (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Ann Rev Cell Dev Biol 22:159–180
15. Kit J, Dickhaut A, Kutter J, Maier HJ, Britton P, Koumans J, Pijlman GP, Fros JJ, Wiegertjes GF, Forlenza M (2015) Infectious bronchitis coronavirus inhibits STAT1 signaling and requires accessory proteins for resistance to type I interferon activity. J Virol 89:12047–12057
16. Kit J, Langereis MA, Maier HJ, Britton P, van Kuppevelt FJ, Koumans J, Wiegertjes GF, Forlenza M (2016) Infectious bronchitis coronavirus limits interferon production by inducing a host shutoff that requires accessory protein 5b. J Virol 90:7519–7528
17. Knoops K, Kikkert M, Worm SH, Zevenhoven-Dobbe JC, van der Meer Y, Koster AJ, Mommaas AM, Snijder EJ (2008) SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol 6:e226
18. Kong L, Shaw N, Yan L, Lou Z, Rao Z (2015) Structural view and substrate specificity of papain-like protease from avian infectious bronchitis virus. J Biol Chem 290:7160–7168
19. Lim KL, Che K, Tan JM, Wang C, Chung K, Zhang Y, Tanaka Y, Smith W, Englelender S, Ross CA, Dawson VL, Dawson TM (2005) Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci Off J Soc Neurosci 25:2002–2009
20. Lin KP, Liu DX (1998) Characterization of the two overlapping papain-like protease domains encoded in gene 1 of the coronavirus infectious bronchitis virus and determination of the C-terminal cleavage site of an 87-kDa protein. Virology 245:303–312
21. Lim KP, Ng LF, Liu DX (2000) Identification of a novel cleavage activity of the first papain-like protease domain encoded by open reading frame 1a of the coronavirus Avian infectious bronchitis virus and characterization of the cleavage products. J Virol 74:1674–1685
22. Lim KP, Ng LFP, Liu DX (2000) Identification of a novel cleavage activity of the first papain-like protease domain encoded by open reading frame 1a of the coronavirus Avian infectious bronchitis virus and characterization of the cleavage products. J Virol 74:1674–1685
23. Liu DX, Brown TD (1995) Characterization and mutational analysis of an ORF 1a-encoding protease domain responsible for proteolytic processing of the infectious bronchitis virus 1a/1b polyprotein. Virology 209:420–427
24. Liu DX, Shen S, Xu HY, Wang SF (1998) Proteolytic mapping of the coronavirus infectious bronchitis virus 1b polyprotein: evidence for the presence of four cleavage sites of the 3C-like protease and identification of two novel cleavage products. Virology 246:288–297
25. Liu DX, Brierley I, Tibbles KW, Brown TD (1994) A 100-kilodalton polypeptide encoded by open reading frame (ORF) 1b of the coronavirus infectious bronchitis virus is processed by ORF 1a products. J Virol 68:5772–5780
26. Sun L, Xing Y, Chen X, Zheng Y, Yang Y, Nichols DB, Clementz MA, Banach BS, Li K, Baker SC, Chen Z (2012) Coronavirus papain-like proteases negatively regulate antiviral innate immune response through disruption of STING-mediated signaling. PloS One 7:e30802
27. Welchman RL, Gordon C, Mayer RJ (2005) Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol 6:599–609
28. Xing Y, Chen J, Tu J, Zhang B, Chen X, Shi H, Baker SC, Feng L, Chen Z (2013) The papain-like protease of porcine epidemic diarrhea virus negatively regulates type I interferon pathway by acting as a viral deubiquitinase. J General Virol 94:1554–1567

29. Zheng D, Chen G, Guo B, Cheng G, Tang H (2008) PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res 18:1105–1113